User:Mr. Ibrahem/Bamlanivimab

Bamlanivimab is medication used to treat COVID-19; however COVID variants including Omicron have developed resistance. While no longer used alone, it continues to be used as part of the combination bamlanivimab/etesevimab. It is given by injection into a vein.

Common side effects include nausea, dizziness, and headache. Other side effects may include anaphylaxis. While safety in pregnancy is unclear, it may be used in pregnancy. It is a monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.

Bamlanivimab received emergency use authorization (EUA) in the United States in November 2020. In April 2021, the EUA was revoked for use alone. The combination remains in use as of December 2021 in certain areas with low resistance. It is not approved in either Europe or the United Kingdom. The United States government paid about 1,250 USD per dose in 2020.